Astro Pak launches decontamination services subsidiary

Published: 26-Jan-2010
Hi Tech Manufacturing Finance Cleaning

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

SixLog, headquartered in Santa Ana, California, performs decontamination services for equipment, rooms, entire buildings and modes of transport such as ambulances, trains and cruise ships.

The iHP bio decontamination technology was developed for military applications and this will be the first time that it will be used in commercial applications.

The company says technology can be used in open air and, once ionised, it acts like a gas as opposed to a vapour, providing excellent distribution properties and destroying micro-organisms even in hard-to-reach areas.

Steve Feinstein, formerly regional sales manager of a UK manufacturer of hydrogen peroxide vapour generators, has been appointed as SixLog's director of technology.

In addition to the company launch, SixLog has developed a website containing technical papers, presentations, and other downloads on biological decontamination and sterilisation.
  • Companies:
  • Instant Cleanroom Solutions
See more

You may also like

Finance

SeaBeLife raises €2 million to advance dual-target cell death therapies

Read more
The funding will help fast-track clinical trials for treatments addressing dry age-related macular degeneration and severe acute hepatitis, supporting the company’s innovative approach to blocking two major regulated cell death pathways

Trending Articles

  1. Prange Pharma to acquire MSD Animal Health manufacturing site in Aprilia, Italy Following completion, the site will relaunch as Aprilia Animal Health, focussing on contract manufacturing of animal health products whilst preserving jobs and expanding European expertise
  2. DaltonTx secures £4m in seed financing to build adaptive, AI-enabled discovery platforms The UK-based technology company's adaptive platform will plug directly into pharma, biotech and CRO workflows, giving teams instant access to AI-enabled discovery
  3. New CGT centre in Bangkok to boost Southeast Asia’s biotech ecosystem eXmoor Pharma and Siam Bioscience form a strategic partnership to establish leading cell and gene therapy services in Southeast Asia
  4. ScaleReady awards nearly $2m in G-Rex grants to advance cell and gene therapy manufacturing in California The initiative supports leading academic GMP facilities in developing scalable, cost-effective platforms for CAR-T and other cell therapies, reinforcing California’s position as a global hub for CGT innovation
  5. EMV Capital subsidiary Moirai acquires Destiny Pharma’s XF-73 antibiotic platform The XF drug platform, designed to prevent bacterial resistance and combat Gram-positive infections such as MRSA, represents a high-impact addition to EMV’s life sciences portfolio

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Finance

SeaBeLife raises €2 million to advance dual-target cell death therapies

The funding will help fast-track clinical trials for treatments addressing dry age-related macular degeneration and severe acute hepatitis, supporting the company’s innovative approach to blocking two major regulated cell death pathways
Research & Development

Daiichi Sankyo launches third global research institute in San Diego

The company expands its international research footprint with a new San Diego institute, strengthening collaborations in one of the world’s leading life-science hubs and advancing its global drug discovery strategy
Finance

Nanologica secures first insulin purification order in China

The SEK 2m deal will see the company’s silica-based NLAB Saga evaluated at production scale by a Chinese insulin manufacturer
Manufacturing

Symbiosis expands sterile manufacturing capacity with fill/finish line qualification

Symbiosis has maintained a track record of successful GMP inspections with both the FDA and MHRA since it was founded
Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
Finance

New CGT centre in Bangkok to boost Southeast Asia’s biotech ecosystem

eXmoor Pharma and Siam Bioscience form a strategic partnership to establish leading cell and gene therapy services in Southeast Asia
Finance

Pfizer to acquire Metsera in $4.9bn deal, expanding obesity drug pipeline with next-generation incretin and amylin therapies

The deal strengthens Pfizer’s position in the fast-growing obesity market, with additional milestone payments of up to $2.3bn tied to key clinical and regulatory achievements
Subscribe now